Adult | Age
Item
adult patients,>/= 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Colorectal Carcinoma | Breast Carcinoma
Item
histological/cytological confirmation of colorectal or breast cancer
boolean
C0009402 (UMLS CUI [1])
C0678222 (UMLS CUI [2])
Patient Ambulatory | Karnofsky Performance Status
Item
patient is ambulatory and has a karnofsky performance status of > 70%
boolean
C0030705 (UMLS CUI [1,1])
C0439841 (UMLS CUI [1,2])
C0206065 (UMLS CUI [2])
Body Surface Area
Item
body surface area between 1.5 and 2.0 m2
boolean
C0005902 (UMLS CUI [1])
Either
Item
either:
boolean
C3844638 (UMLS CUI [1])
Etiology | Xeloda | Combined Modality Therapy
Item
due to receive xeloda as monotherapy or as combination therapy as per their treating physician's treatment plan, or
boolean
C0015127 (UMLS CUI [1])
C0724419 (UMLS CUI [2])
C0009429 (UMLS CUI [3])
Xeloda | Ability Receive Investigational New Drugs
Item
currently receiving xeloda monotherapy and in the investigator's opinion able to tolerate study drug dose on day 1 and day 2
boolean
C0724419 (UMLS CUI [1])
C0085732 (UMLS CUI [2,1])
C1514756 (UMLS CUI [2,2])
C0013230 (UMLS CUI [2,3])
Medical contraindication Xeloda
Item
any contraindication to xeloda
boolean
C1301624 (UMLS CUI [1,1])
C0724419 (UMLS CUI [1,2])
Xeloda Received Recently
Item
received xeloda in the 6 days prior to day 1
boolean
C0724419 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
Organ allografts | Exception Autologous bone marrow transplant Post High-dose chemotherapy
Item
subjects with organ allografts (other than autologous bone marrow transplant after high dose chemotherapy)
boolean
C0178784 (UMLS CUI [1,1])
C0040739 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0194037 (UMLS CUI [2,2])
C0687676 (UMLS CUI [2,3])
C1328050 (UMLS CUI [2,4])
Renal Insufficiency
Item
renal impairment
boolean
C1565489 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating females
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
participation in an investigational drug study within 28 days prior to screening
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Lacking Integrity Upper Gastrointestinal Tract | Malabsorption Syndrome
Item
lack of physical integrity of the upper gastrointestinal tract, or clinically significant malabsorption syndrome
boolean
C0332268 (UMLS CUI [1,1])
C1947912 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,3])
C0024523 (UMLS CUI [2])
Communicable Diseases Serious Uncontrolled
Item
serious uncontrolled intercurrent infections
boolean
C0009450 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0205318 (UMLS CUI [1,3])
Coronary Artery Disease
Item
history of clinically significant coronary artery disease
boolean
C1956346 (UMLS CUI [1])
Warfarin therapy
Item
concomitant treatment with warfarin
boolean
C4303340 (UMLS CUI [1])
Dihydropyrimidine Dehydrogenase Deficiency
Item
known dihydropyrimidine dehydrogenase deficiency
boolean
C1959620 (UMLS CUI [1])